http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The effect of acrylic silane crosslinker on room‐temperature cured acrylate binder for road markings
Jang Dong Gyu,Lim Won‐Bin,Bae Ji‐Hong,Lee Ju‐Hong,Min Jin‐Gyu,Kim Ju‐Won,Yoon Keun‐Byoung,Huh PilHo 대한화학회 2022 Bulletin of the Korean Chemical Society Vol.43 No.8
An acrylic binder with excellent physical properties is prepared using copolymer of methyl methacrylate (MMA) and butyl acrylate monomer (BAM), 2-hydroxyethyl methacrylate (2-HEMA), 3-(trimethoxysilyl)propyl methacrylate (TMSPMA), and additives. The obtained acrylic resins are subjected to a redox initiator system (ROIS) for room temperature curing. The effects of the TMSPMA concentration and [acryl-copolymer]/[2-HEMA] ratio on backbone content are studied in terms of traffic marking paint. The mechanical and morphological properties are thoroughly evaluated using universal testing machine (UTM), UV spectrum, and SEM. With increasing TMSPMA content, the adhesive strength and transmittance of the cured resins increase up to a limiting value of TMSPMA content because of the optimizing crosslink network in backbone structure. The introduction of TMSPMA may be effectively attributed to strong adhesive and high transparency of an acrylic resin series. Consequently, acrylic resins with optimal TMSPMA content can be mostly utilized as a highperformance binder in the traffic marking paint field.
( Ju Hyun Lee ),( Junhyeon Cho ),( Sanghyuk Im ),( Beom Hee Kim ),( Chung Seop Lee ),( Jung Wha Chung ),( Yung Jung Kim ),( Eun Sun Jang ),( Jin-wook Kim ),( Hong Bin Kim ),( Sook-hyang Jeong ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Health care workers (HCW) are at high risk of sharp injury including needle stick injuries, percutaneous and mucocutaneous injuries. Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) are causes of sharp injury-related infection. The aims of this study were to elucidate the incidence density and epidemiological characteristics of sharp injury among HCW, and to investigate the transmission rate of HBV, HCV and HIV in a Korean university hospital. Methods: This retrospective cohort study analyzed the data from the HCW self-reporting system for sharp injury, which is integrated in electronic healthcare recording system and managed by Occupational Safety and Health Office from January 2011 to December 2015. The incidence density per 100 persons (full-time equivalent employees)-year of sharp injury was calculated. Descriptive analysis was performed on the characteristics of sharp injury and transmission rate of HBV, HCV, and HIV. Results: A total of 1,076 occupational blood exposures were reported during 5 year. The total HCW number was 10,452, and the average yearly bed number was 1,072. Overall incidence density of sharp injury was 5.6 cases per 100 person-year, and 20.3 per 100 bed-year. Among the occupation type, housekeeping people in janitorial service company working in hospital wards showed the highest rate of sharp injury (14.8%) followed by doctors (8.5%) and nurses (6.2%). The most common place of sharp injury was wards, emergency room, and operating room (38.1%, 13.3% and 12.2%, respectively). The percutaneous injury accounted for 86.7% and mucocutaneous injury for 13.2%. During the 5 years, incidence rate tends to gradually decrease, and bed number per HCW was significantly associated with incidence density of sharp injury during the study period. Among the source patients, HBV, HCV, and HIV was positive in 133/681 (19%), 126/680 (18.5%) and 25/657 patients (3.8%), respectively. However, only one HCW was infected by HCV, showing HCV transmission rate of 0.8%. Neither HBV nor HIV infection occurred. Conclusions: The current incidence rate of sharp injury in a Korean university hospital HCW by highly encouraged easy reporting system was 5.6 cases per 100 person-year, and 20.3 per 100 bed-year, showing the highest incidence in housekeeping people in janitorial service company working in hospital wards. The transmission rate of HCV was less than 1%, while there was no transmitted case of HBV or HIV. Preventive measures to reduce sharp injury for HCW should be continued.
Jang, Mi-Hyeon,Kim, Hong,Shin, Min-Chul,Lim, Baek-Vin,Lee, Taeck-Hyun,Jung, Sae-Bin,Kim, Chang-Ju,Kim, Ee-Hwa WHO COLLABORATING CENTRE FOR TRADITIONAL MEDICINE 2002 東西醫學硏究所 論文集 Vol.2002 No.-
ABSTRACT-Folium mori, the leaves of Morus alba L., has traditionally been used for the treatment of diabetic hyperglycemia. It has been shown to induce enhanced NOS expression in the hypothalamus of rats with streptozotocin(S72)-induced diabetes. In the present study, the effect of Folium mori on the expression of nitric oxide synthase (NOS) in the hypothalamus of STZ-induced diabetic rats was investigated via nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH-d) histochemlstry. Enhanced NAPDH-d expression was detected in the paraventncular nucleus, ventromedial hypothalamic nucleus, and lateral hypo-thalamic area of the hypothalamus in the STZ-induced diabetes group. Administration of the aqueous extract of Folium mori to rats with STZ-induced diabetes resulted in decreased NADPH-d positivity. These results suggest that Folium mori treatment is effective in curbing the desire for food under diabetic conditions via modulation of NO expression in the hypothalamus.
Jang Heejoon,Yu Su Jong,Lee Hong Ghi,Kim Tae Min,Lee Yun Bin,Cho Eun Ju,Lee Jeong-Hoon,Yoon Jung-Hwan,Kim Yoon Jun 대한의학회 2023 Journal of Korean medical science Vol.38 No.28
Background: Rituximab occasionally induces reactivation of hepatitis B virus (HBV) in patients with resolved HBV, at times with fatal consequences. The optimal duration of prophylactic antiviral therapy in this situation is unclear. We aimed to investigate the difference in HBV reactivation according to the duration of prophylactic tenofovir disoproxil fumarate (TDF) in patients with resolved HBV and receiving rituximab. Methods: A multicenter, randomized, open-label, prospective study was conducted in hepatitis B surface antigen-negative and anti-HBc-positive non-Hodgkin’s lymphoma patients treated with rituximab-based chemotherapy. A total of 90 patients were randomized and received prophylactic TDF from the initiation of rituximab until 6 months (the 6-month group) or 12 months (the 12-month group) after the completion of rituximab. The primary outcome was the difference in HBV reactivation and the secondary outcomes were the difference in hepatitis flare and adverse events between the two groups. Results: In an intention to treat (ITT) analysis, HBV reactivation occurred in 1 of 43 patients (2.3%; 95% confidence interval [CI], 0.41–12%) at a median of 13.3 months in the 6-month group and 2 of 41 patients (4.9%; 95% CI, 1.4–16%) at a median of 13.7 months in the 12-month group. In a per protocol (PP) analysis, HBV reactivation occurred in 1 of 18 patients (5.6%; 95% CI, 0.99–26%) at 13.3 months in the 6-month group and 1 of 13 patients (7.7%; 95% CI, 1.4–33%) at 9.7 months in the 12-month group. The cumulative incidence of HBV reactivation was not significantly different between the two groups in ITT and PP analyses (P = 0.502 and 0.795, respectively). The occurrence of adverse events was not significantly different between the two groups in ITT (9.3% in the 6-month group, 22.0% in the 12-month group, P = 0.193) and PP analyses (5.6% in the 6-month group, 7.7% in the 12-month group, P > 0.999). Conclusion: Prophylactic TDF up to 6 months after completion of rituximab-based chemotherapy is sufficient in terms of the efficacy and safety of reducing HBV reactivation in patients with resolved HBV.